Addressing strategic challenges for biotech companies

About our guest

Dr. Srikanth Rajagopal, is a Partner at Clarivate Consulting, based out of London. Doc has over 15 years global management experience. Areas of expertise include product and portfolio strategy, pricing, reimbursement and access across Europe and Emerging Markets, transaction advisory and commercial strategy. Doc’s recent vaccine experience includes digital / multi-marketing strategy for the UK business unit of a large multinational vaccines company, competitive risk assessment for the vaccines portfolio of a large multinational vaccines company and an assessment of compliance for vaccines across European markets. Doc holds an MBA from the Indian Institute of Management, Ahmedabad and an MBBS (MD equivalent) from the University of Mumbai.

About our host

Mike Ward serves as Global Head of Thought Leadership at Clarivate. As both a journalist and analyst, Mike has been writing, analyzing and commenting on the life sciences industry for more than 35 years. He has held editorial and content leadership roles at various publications and organizations across the industry.

Creating an accurate picture of your asset’s commercial options (7mins)

In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at Clarivate talks to Dr Srikanth Rajagopal (or Doc, as he is fondly referred to). Doc, a partner at Clarivate Consulting, whose areas of expertise include product and portfolio strategy to name a few, chatted to us about common strategic challenges biotechnology companies face during the process of translating a discovery into a tangible medicine. Doc provides invaluable insight for biopharma companies who are making development and/or commercial decisions for their clinical programs, both for those developing in house and those considering out-licensing. He explores pertinent examples of how companies can go about understanding the commercial opportunity of their efficacious treatments in various scenarios and markets (including orphan indications) and discusses what he calls the ‘magic triangle’ to get an asset to market as fast as possible.

Understanding Commercial Opportunity for efficacious treatments (8mins)

In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at Clarivate talks to Dr Srikanth Rajagopal (or Doc, as he is fondly referred to). Doc, a partner at Clarivate Consulting, whose areas of expertise include product and portfolio strategy to name a few, chatted to us about common strategic challenges biotechnology companies face during the process of translating a discovery into a tangible medicine. Doc provides invaluable insight for biopharma companies who are making development and/or commercial decisions for their clinical programs, both for those developing in house and those considering out-licensing. He explores pertinent examples of how companies can go about understanding the commercial opportunity of their efficacious treatments in various scenarios and markets (including orphan indications) and discusses what he calls the ‘magic triangle’ to get an asset to market as fast as possible.

Key commercial factors to consider during program development to forecast share of voice (11mins)

In this Conversations in Healthcare highlight, Mike Ward, Global Head of Thought Leadership at Clarivate talks to Clarivate Consulting Partner, Dr Srikanth Rajagopal (or Doc, as he is fondly referred to) about the key approaches biotech management teams should be considering during asset development to ensure they can win share of patient and physician voice for their alternatives in crowded markets. Doc talks us through the importance of understanding the value and risks of differing in-house and out-license commercialisation alternatives and the interesting partnership discussions that are often triggered when companies think they have reached the end of the road with an asset.